scispace - formally typeset
D

David Perez

Researcher at University of Otago

Publications -  28
Citations -  1113

David Perez is an academic researcher from University of Otago. The author has contributed to research in topics: Bevacizumab & Oxaliplatin. The author has an hindex of 10, co-authored 28 publications receiving 969 citations.

Papers
More filters
Journal ArticleDOI

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

Harpreet Wasan, +197 more
- 01 Sep 2017 - 
TL;DR: Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with coloreCTal liver metastases with liver-dominant disease after chemotherapy.
Journal ArticleDOI

The use of quality of life data in clinical practice

TL;DR: The main barriers to collecting QoL data are logistic and the challenge remains to develop a method of collecting and analysingQoL information in a manner which enhances decision making.
Journal ArticleDOI

A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.

TL;DR: It is indicated that an epirubicin dose of 90 mg/m2 produces toxicity equivalent to doxorubicIn but does not improve response rates, response duration, or survival in advanced breast cancer.
Journal ArticleDOI

Epigenetic silencing in non‐neoplastic epithelia identifies E‐cadherin (CDH1) as a target for chemoprevention of lobular neoplasia

TL;DR: The findings suggest that chemoprevention of LBC by epigenetic drugs should be feasible and the presence of CDH1 methylation in pre‐neoplastic epithelia suggests the existence of mammary regions with increased disease susceptibility, providing an explanation for the often multifocal presentation of L BC.